Pulmonary Arterial Hypertension Market

May 08, 2020

10 likes | 20 Views

According to DelveInsight, the market size of Pulmonary Arterial Hypertension in 7MM was found to be USD 4.6 Billion in 2017. Among the 7MM, the United States accounts for the largest market size of Pulmonary Arterial Hypertension, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. The total number of prevalent cases of Pulmonary Arterial Hypertension (PAH) in 7MM was found to be 70,774, in the year 2017. The key players in the Pulmonary Arterial Hypertension market include United Therapeutics Corporation, Liquidia Technologies, Reata Pharmaceuticals, Altavant Sciences, Acceleron Pharma, PhaseBio Pharmaceuticals, Complexa, Arena Pharmaceuticals, Johnson & Johnson, GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc., Bayer AG, Pfizer, Bellerophon Pulse Technologies, and many others. For more information visit: https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pah-market#infographics #bloodpressure #bp #Pulmonaryarterialhypertension #hypertension

DelveInsight

Download Presentation

Pulmonary Arterial Hypertension Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D